C
Catalent
Enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world
About Catalent
Catalent is a global leader in enabling pharmaceutical, biotechnology, and consumer health partners to optimize their product development, launch, and full lifecycle supply. The company operates in the healthcare market, serving clients ranging from large pharmaceutical companies to emerging biotech firms. Catalent's business model focuses on providing comprehensive solutions that enhance the efficiency and effectiveness of drug development and delivery. This includes services such as drug formulation, manufacturing, clinical supply, and commercial packaging. Catalent generates revenue through long-term contracts and partnerships with its clients, offering tailored solutions that meet the specific needs of each project. The company is committed to high business standards, corporate responsibility, and sustainability, actively working to reduce greenhouse gas emissions, waste, and water use. Catalent also invests in its communities by promoting STEM education and supporting diverse and inclusive workplaces.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1996
- Headquarters
- Franklin Township, United States
- Listing
- IPO 2014
- Employees
- 9,028
- Open positions
- 183
- Dealroom signal
- 29.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Clinical, Innovation Radar, Tech for Biotech and Pharma, Drug Delivery Systems, Manufacturing
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 9 companies, latest Aug 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBT✓Debt | Aug 2026 | $4.1B | — | JP Morgan · Morgan Stanley | ↗ |
| ACQUISITION✓Exit | Feb 2024 | $17B | $17B | Novo Holdings | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Catalent is 120K monthly website visits, up 20% over the last three months. Catalent's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Metrics Contract ServicesOak Island, United StatesFull-service contract development and manufacturing organization (cdmo) specializing in oral dosage forms
$475Mvaluation
BH
Bettera HoldingsPlano, United States
$1Bvaluation
RCT Stemcell BiotechLangenfeld, GermanyCell therapy and process development
→
Delphi Genetics S.A.Charleroi, BelgiumAntibiotic-free plasmid DNA bioproduction for gene therapies
→
MaSTherCellCharleroi, BelgiumCell and gene therapy contract manufacturing services
$315Mvaluation
Paragon BioservicesBaltimore, United StatesCro-cmo whose focus is biopharmaceuticals
$1.2Bvaluation
CP
Cook Pharmica,Bloomington, United StatesPrivately held contract development and manufacturing organization
→
Pharmatek LaboratriesSan Diego, United StatesPharmaceutical chemistry development and manufacturing company
→
Catalent Micron TechnologiesMalvern, United StatesA Malvern, Penn-based provider of particle-size engineering technologies
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Cardinal Health
Elliott Management
JP Morgan
Morgan Stanley
Other known investors2 additional known investors
Novo Holdings
Aisling Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Catalent on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Catalent’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.